Alpa Laboratories: Should You Buy, Hold, or Sell Right Now?
- September 7, 2026
- Posted by: Lakshit Sharma
- Category: Market
Alpa Laboratories share price Rs 63.69 (NSE), well off its 52-week high. 52-week range Rs 46 to Rs 99.75. Q1 FY27 profit fell sharply against an unusually high year-ago base.
Quick Answer
Alpa Laboratories Ltd share price is trading around Rs 64, more than 36 percent below its 52-week high of Rs 99.75 but above its 52-week low of Rs 46. Q1 FY27 revenue fell 4.3 percent year on year to Rs 29.70 crore, with net profit down sharply to Rs 0.98 crore from Rs 11.77 crore, though the year-earlier Q1 FY26 quarter’s unusually high profit appears to reflect a one-off item, given subsequent quarters through FY26 ran between Rs 0.11 crore and Rs 1.59 crore. Full-year FY25 profit grew 16.2 percent to Rs 19.50 crore from Rs 16.78 crore in FY24. The stock trades at a discount of 32.89 times earnings against the pharma sector average near 37.7 times.
Alpa Laboratories share price has fallen more than 36 percent from its 52-week high of Rs 99.75, with Alpa Laboratories share price now trading near Rs 64 on the NSE, above its 52-week low of Rs 46. Given a Q1 FY27 profit comparison distorted by an unusually high year-ago base, this article explains that plainly before laying out a balanced view.
This Alpa Laboratories stock analysis walks through the Q1 FY27 numbers, the distorted year-on-year comparison, valuation against the pharmaceutical sector, shareholding pattern and the technical setup, using figures sourced from public filings.
Click Here – Get Free Investment Predictions
About Alpa Laboratories
Before deciding on Alpa Laboratories share price, it helps to understand the underlying business. Alpa Laboratories Ltd. manufactures pharmaceutical formulations, serving domestic and export markets with a range of branded and generic medicines.
As a pharmaceutical formulations manufacturer, Alpa Laboratories’ quarterly profit has shown considerable variability, with the June 2025 quarter’s unusually high profit of Rs 11.77 crore standing well above the roughly Rs 0.1 crore to Rs 1.6 crore range seen in every other recent quarter, suggesting a one-off item rather than a representative run rate.
Alpa Laboratories Share Price Today: Key Levels
The table below summarises where Alpa Laboratories share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Alpa Laboratories CMP (NSE) | Rs 63.69 |
| Alpa Laboratories CMP (BSE) | Rs 64.12 |
| 52-Week High | Rs 99.75 |
| 52-Week Low | Rs 46.00 |
| Market Capitalisation | Approximately Rs 134 crore |
Alpa Laboratories share price is trading well below its 52-week high, reflecting the market’s reaction to the sharp year-on-year profit decline, though this comparison is distorted by an unusually high prior-year base.
Check the Univest Screener for Live Stock Data
Alpa Laboratories Financial Performance
The Alpa Laboratories share price trend is closely tied to how these numbers evolve each quarter. Alpa Laboratories reported Q1 FY27 (June 2026 quarter) revenue of Rs 29.70 crore, down 4.3 percent year on year from Rs 31.05 crore, with net profit of Rs 0.98 crore, down sharply from Rs 11.77 crore in the year-earlier quarter. However, every other quarter across FY26, including September at Rs 0.11 crore, December at Rs 1.59 crore and March at Rs 1.38 crore, ran well below the June 2025 figure, suggesting that quarter included a one-off item rather than representing the company’s typical run rate.
For the full year FY25, the company reported revenue of Rs 135.80 crore, up 9.8 percent year on year, with net profit of Rs 19.50 crore, up 16.2 percent from Rs 16.78 crore in FY24, showing solid annual growth even accounting for the unusual June 2025 quarter within that year.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Q1 FY27 (Jun 2026) | Rs 29.70 crore | Rs 0.98 crore | Compared against an unusually high Rs 11.77 crore year-ago quarter |
| FY25 (full year) | Rs 135.80 crore | Rs 19.50 crore | +9.8% revenue, +16.2% profit YoY |
Valuation Check: Is Alpa Laboratories Share Price Expensive?
Any view on Alpa Laboratories share price should start from these valuation multiples. Alpa Laboratories share price currently reflects a price to earnings ratio of about 32.89 times trailing earnings, a discount to the broader pharmaceutical sector average of roughly 37.7 times. The price to book ratio stands at 0.72 times, meaning the stock trades below its own reported book value.
Debt to equity of 0.01 is very low. Given that trailing earnings are elevated by the unusual June 2025 quarter, the reported PE should be read with some caution, as underlying quarterly profitability outside that quarter has typically run at a smaller scale.
Technical Signals: What the Chart Shows
Price action here often foreshadows the next move in Alpa Laboratories share price. Alpa Laboratories share price is currently positioned more than 36 percent below its 52-week high of Rs 99.75 and above its 52-week low of Rs 46, reflecting the market’s reaction to the sharp year-on-year profit decline. A stock trading here after such a decline often reflects the market recalibrating expectations once the distorting effect of the unusual prior-year quarter is understood.
Trading volumes remain very light, so investors should track Alpa Laboratories share price alongside continued quarterly results at their normalised, more typical run rate, rather than anchoring to the unusually high June 2025 comparison at these technical levels.
Download the Univest iOS App or Univest Android App to track Alpa Laboratories’ live price and technical levels.
Shareholding Pattern
Shifts here can influence Alpa Laboratories share price more than headline news on some sessions. Alpa Laboratories is a promoter-led pharmaceutical formulations manufacturer. A detailed current promoter, FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company’s latest exchange filing.
Why Investors Are Watching Alpa Laboratories
- Solid underlying FY25 annual growth: Full-year FY25 profit grew 16.2 percent year on year, a healthy pace once the distorting effect of the single unusual quarter is set aside.
- Trading below book value: A price to book ratio of 0.72 times suggests the stock trades at a discount to its own reported net asset value.
- Very low financial leverage: A debt to equity ratio of just 0.01 gives the company significant financial flexibility.
Risks and Factors to Watch
- Distorted year-on-year comparison: The Q1 FY27 profit decline looks dramatic only because it is measured against an unusually high year-ago quarter; investors should focus on the more typical quarterly run rate instead.
- Small absolute profit base in most quarters: With typical quarterly profit in the range of Rs 0.1 crore to Rs 1.6 crore, the business operates on a small scale where percentage swings can look large even on modest rupee changes.
- Pharmaceutical formulations competitive market: Alpa Laboratories competes against numerous domestic and international pharmaceutical formulations manufacturers.
- Small-cap liquidity risk: As a small-cap stock with a market capitalisation of approximately Rs 134 crore, trading liquidity can be more limited than larger peers.
Alpa Laboratories Share Price Target: What the Data Suggests
Until then, Alpa Laboratories share price remains best tracked through live, verified data rather than a single fixed number. Alpa Laboratories does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time, given the distorted year-on-year comparison involved.
Investors considering this stock should track the Univest Screener for continued quarterly updates, and should consult a SEBI-registered investment adviser for guidance tailored to their own goals.
Alpa Laboratories: Should You Buy, Hold, or Sell Right Now?
This is the core question behind Alpa Laboratories share price right now. The Alpa Laboratories buy or sell decision should look past the distorted headline year-on-year comparison.
The case for buying: Value-focused investors who understand the June 2025 quarter’s unusual profit and see the below-book valuation alongside solid FY25 annual growth as attractive may find the current level worth considering.
The case for holding: Existing shareholders who already understand this distortion may choose to continue holding based on the underlying FY25 growth trend.
The case for waiting: Investors wanting to see a few more quarters at the company’s typical run rate before committing fresh capital may prefer to wait for that confirmation.
Weigh this against your own risk tolerance and consult a SEBI-registered investment adviser if unsure.
Conclusion
Alpa Laboratories share price reflects a pharmaceutical formulations manufacturer whose Q1 FY27 profit decline looks dramatic mainly due to an unusually high year-ago comparison quarter, with solid underlying FY25 annual growth, trading well below its 52-week high at a discount to the pharma sector. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is Alpa Laboratories a good stock to buy right now?
Ans. Alpa Laboratories’ Q1 FY27 profit fell sharply, but this is compared against an unusually high year-ago quarter of Rs 11.77 crore that stands out from every other recent quarter’s Rs 0.1 crore to Rs 1.6 crore range. Full-year FY25 profit actually grew 16.2 percent, which may appeal to value-focused investors who understand this distortion.
Q2. What is the Alpa Laboratories share price today?
Ans. Alpa Laboratories share price is trading around Rs 64 on the NSE. The stock’s 52-week high is Rs 99.75 and its 52-week low is Rs 46.
Q3. What is the Alpa Laboratories share price target?
Ans. Alpa Laboratories does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time, given the distorted year-on-year comparison involved.
Q4. Why did Alpa Laboratories’ profit fall so much in Q1 FY27?
Ans. Alpa Laboratories’ Q1 FY27 profit of Rs 0.98 crore looks like a sharp decline only because it is compared against an unusually high Rs 11.77 crore profit in the year-ago quarter, which appears to reflect a one-off item given every other recent quarter ran between Rs 0.1 crore and Rs 1.6 crore.
Q5. What does Alpa Laboratories manufacture?
Ans. Alpa Laboratories manufactures pharmaceutical formulations, serving domestic and export markets.
Q6. What is Alpa Laboratories’ market capitalisation and PE ratio?
Ans. Alpa Laboratories has a market capitalisation of approximately Rs 134 crore and trades at a price to earnings ratio of about 32.89 times, a discount to the pharmaceutical sector average PE of roughly 37.7 times.